| 37.16 -1.35 (-3.51%) | 10-30 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 45.23 | 1-year : | 52.82 |
| Resists | First : | 38.72 | Second : | 45.23 |
| Pivot price | 34.04 |
|||
| Supports | First : | 34.36 | Second : | 31.67 |
| MAs | MA(5) : | 36.02 |
MA(20) : | 34.08 |
| MA(100) : | 29.89 |
MA(250) : | 30.35 |
|
| MACD | MACD : | 0.6 |
Signal : | 0.1 |
| %K %D | K(14,3) : | 87.4  |
D(3) : | 82.9 |
| RSI | RSI(14): 60.7 |
|||
| 52-week | High : | 44.27 | Low : | 17.72 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ CSTL ] has closed below upper band by 8.2%. Bollinger Bands are 44% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 0 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 38.35 - 38.54 | 38.54 - 38.67 |
| Low: | 36.23 - 36.48 | 36.48 - 36.64 |
| Close: | 36.78 - 37.16 | 37.16 - 37.4 |
Castle Biosciences, Inc. functions as a commercial-stage diagnostics firm, with its primary objective being the provision of both diagnostic and prognostic testing services, specifically targeting various dermatological cancers. Their flagship product, DecisionDx-Melanoma, represents an advanced multi-gene expression profile (GEP) assay engineered to assess the probability of metastasis in patients afflicted with invasive cutaneous melanoma. In addition to their leading solution, the company has created several other specialized, proprietary tests. Among these is DecisionDx-UM, a GEP test tailored to forecast the risk of metastasis for individuals with uveal melanoma, a less common malignancy of the eye. Another key offering is DecisionDx-SCC, a distinctive 40-gene expression profile test that utilizes a patient's unique tumor biology to predict their specific risk of squamous cell carcinoma metastasis, particularly for those presenting with recognized risk factors. Moreover, they offer DecisionDx DiffDx-Melanoma and myPath Melanoma, both proprietary GEP tests employed to assist in the accurate diagnosis of ambiguous pigmented lesions. These specialized testing services are provided by Castle Biosciences to patients predominantly through their healthcare providers. The organization commenced operations in 2007 and maintains its corporate headquarters in Friendswood, Texas.
Sun, 01 Nov 2026
Castle Biosciences (NASDAQ:CSTL) Stock Rating Raised to Buy at Wall Street Zen - MarketBeat
Fri, 30 Oct 2026
Castle Biosciences (CSTL) Chief Commercial Officer Tobin Juvenal Sells 6,578 Shares - GuruFocus
Fri, 30 Oct 2026
Under a preset trading plan, Castle Biosciences (CSTL) executive sells 6,578 shares. - Stock Titan
Wed, 28 Oct 2026
Castle Biosciences (CSTL) Chief Commercial Officer Tobin Juvenal Sells 3,288 Shares - GuruFocus
Wed, 28 Oct 2026
Under a trading plan, Castle Biosciences (CSTL) officer sells 3,288 shares at an average $33.08. - Stock Titan
Wed, 28 Oct 2026
Castle Biosciences to Participate in Upcoming Investor Conferences - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Diagnostics & Research
|
|
| Shares Out | 31 (M) |
| Shares Float | 27 (M) |
| Held by Insiders | 2.3 (%) |
| Held by Institutions | 91 (%) |
| Shares Short | 2,000 (K) |
| Shares Short P.Month | 1,980 (K) |
| EPS | -0.64 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 15.4 |
| Profit Margin | -5.5 % |
| Operating Margin | -3 % |
| Return on Assets (ttm) | -1.4 % |
| Return on Equity (ttm) | -4.2 % |
| Qtrly Rev. Growth | 20.1 % |
| Gross Profit (p.s.) | 9.03 |
| Sales Per Share | 11.69 |
| EBITDA (p.s.) | -0.55 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 43 (M) |
| Levered Free Cash Flow | -7 (M) |
| PE Ratio | -58.04 |
| PEG Ratio | 0 |
| Price to Book value | 2.41 |
| Price to Sales | 3.17 |
| Price to Cash Flow | 26.61 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|